Difference between revisions of "Melanoma"
m (Text replace - "content property of HemOnc.org" to "content property of [http://hemonc.org HemOnc.org]") |
(added regimens) |
||
Line 5: | Line 5: | ||
{{TOC limit|limit=2}} | {{TOC limit|limit=2}} | ||
− | ==Carboplatin | + | ==Carboplatin & Paclitaxel (CP)== |
+ | CP: '''<u>C</u>'''arboplatin, '''<u>P</u>'''aclitaxel | ||
+ | |||
===Regimen #1, Rao, et al. 2006=== | ===Regimen #1, Rao, et al. 2006=== | ||
*[[Carboplatin (Paraplatin)]] AUC 2 IV on days 1, 8, 15 | *[[Carboplatin (Paraplatin)]] AUC 2 IV on days 1, 8, 15 | ||
Line 18: | Line 20: | ||
'''21-day cycles''' | '''21-day cycles''' | ||
− | ===Regimen #3, Hauschild, et al. 2009=== | + | ===Regimen #3, Hauschild, et al. 2009 & Flaherty, et al. 2013 (E2603)=== |
− | *[[Carboplatin (Paraplatin)]] AUC 6 IV on day 1 | + | *[[Carboplatin (Paraplatin)]] AUC 6 IV over 30 minutes once on day 1, given second |
− | *[[Paclitaxel (Taxol)]] 225 mg/m2 IV on day 1 | + | *[[Paclitaxel (Taxol)]] 225 mg/m2 IV over 3 hours once on day 1, given first |
− | '''21-day cycles x | + | '''21-day cycles x 4 cycles, then''' |
− | *[[Carboplatin (Paraplatin)]] AUC 5 IV on day 1 | + | *[[Carboplatin (Paraplatin)]] AUC 5 IV over 30 minutes once on day 1, given second |
− | *[[Paclitaxel (Taxol)]] 175 mg/m2 IV on day 1 | + | *[[Paclitaxel (Taxol)]] 175 mg/m2 IV over 3 hours once on day 1, given first |
− | '''21-day cycles x | + | '''21-day cycles x 6 cycles, until progression of disease, or unacceptable toxicity''' |
===References=== | ===References=== | ||
# Rao RD, Holtan SG, Ingle JN, Croghan GA, Kottschade LA, Creagan ET, Kaur JS, Pitot HC, Markovic SN. Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma. Cancer. 2006 Jan 15;106(2):375-82. [http://onlinelibrary.wiley.com/doi/10.1002/cncr.21611/full link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/16342250 PubMed] | # Rao RD, Holtan SG, Ingle JN, Croghan GA, Kottschade LA, Creagan ET, Kaur JS, Pitot HC, Markovic SN. Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma. Cancer. 2006 Jan 15;106(2):375-82. [http://onlinelibrary.wiley.com/doi/10.1002/cncr.21611/full link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/16342250 PubMed] | ||
# Hauschild A, Agarwala SS, Trefzer U, Hogg D, Robert C, Hersey P, Eggermont A, Grabbe S, Gonzalez R, Gille J, Peschel C, Schadendorf D, Garbe C, O'Day S, Daud A, White JM, Xia C, Patel K, Kirkwood JM, Keilholz U. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol. 2009 Jun 10;27(17):2823-30. Epub 2009 Apr 6. [http://jco.ascopubs.org/content/27/17/2823.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/19349552 PubMed] | # Hauschild A, Agarwala SS, Trefzer U, Hogg D, Robert C, Hersey P, Eggermont A, Grabbe S, Gonzalez R, Gille J, Peschel C, Schadendorf D, Garbe C, O'Day S, Daud A, White JM, Xia C, Patel K, Kirkwood JM, Keilholz U. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol. 2009 Jun 10;27(17):2823-30. Epub 2009 Apr 6. [http://jco.ascopubs.org/content/27/17/2823.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/19349552 PubMed] | ||
+ | # Flaherty KT, Lee SJ, Zhao F, Schuchter LM, Flaherty L, Kefford R, Atkins MB, Leming P, Kirkwood JM. Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma. J Clin Oncol. 2013 Jan 20;31(3):373-9. doi: 10.1200/JCO.2012.42.1529. Epub 2012 Dec 17. [http://jco.ascopubs.org/content/31/3/373.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/23248256 PubMed] | ||
− | ==Carboplatin | + | ==Carboplatin, Paclitaxel, Sorafenib== |
− | |||
− | |||
− | |||
− | |||
− | |||
− | ''' | + | ===Regimen, Hauschild, et al. 2009 & Flaherty, et al. 2013 (E2603)=== |
+ | ''Hauschild, et al. 2009 and Flaherty, et al. 2013 (E2603) were negative studies. They did not show improved outcomes for Carboplatin, Paclitaxel, Sorafenib as compared to Carboplatin and Paclitaxel.'' | ||
+ | *[[Carboplatin (Paraplatin)]] AUC 6 IV over 30 minutes once on day 1, given second | ||
+ | *[[Paclitaxel (Taxol)]] 225 mg/m2 IV over 3 hours once on day 1, given first | ||
+ | *[[Sorafenib (Nexavar)]] 400 mg PO BID on days 2 to 19 | ||
− | + | '''21-day cycles x 4 cycles, then''' | |
− | |||
− | |||
− | + | *[[Carboplatin (Paraplatin)]] AUC 5 IV over 30 minutes once on day 1, given second | |
+ | *[[Paclitaxel (Taxol)]] 175 mg/m2 IV over 3 hours once on day 1, given first | ||
+ | *[[Sorafenib (Nexavar)]] 400 mg PO BID on days 2 to 19 | ||
− | + | '''21-day cycles x 6 cycles, until progression of disease, or unacceptable toxicity; then proceed to sorafenib monotherapy''' | |
− | '''given until progression of disease or unacceptable toxicity''' | + | ====Sorafenib monotherapy==== |
+ | *[[Sorafenib (Nexavar)]] 400 mg PO BID on days 1 to 21 | ||
+ | |||
+ | '''21-day cycles, given until progression of disease or unacceptable toxicity''' | ||
===References=== | ===References=== | ||
− | |||
# Hauschild A, Agarwala SS, Trefzer U, Hogg D, Robert C, Hersey P, Eggermont A, Grabbe S, Gonzalez R, Gille J, Peschel C, Schadendorf D, Garbe C, O'Day S, Daud A, White JM, Xia C, Patel K, Kirkwood JM, Keilholz U. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol. 2009 Jun 10;27(17):2823-30. Epub 2009 Apr 6. [http://jco.ascopubs.org/content/27/17/2823.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/19349552 PubMed] | # Hauschild A, Agarwala SS, Trefzer U, Hogg D, Robert C, Hersey P, Eggermont A, Grabbe S, Gonzalez R, Gille J, Peschel C, Schadendorf D, Garbe C, O'Day S, Daud A, White JM, Xia C, Patel K, Kirkwood JM, Keilholz U. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol. 2009 Jun 10;27(17):2823-30. Epub 2009 Apr 6. [http://jco.ascopubs.org/content/27/17/2823.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/19349552 PubMed] | ||
− | # | + | # Flaherty KT, Lee SJ, Zhao F, Schuchter LM, Flaherty L, Kefford R, Atkins MB, Leming P, Kirkwood JM. Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma. J Clin Oncol. 2013 Jan 20;31(3):373-9. doi: 10.1200/JCO.2012.42.1529. Epub 2012 Dec 17. [http://jco.ascopubs.org/content/31/3/373.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/23248256 PubMed] |
==Cisplatin (Platinol), Dacarbazine (DTIC) +/- Carmustine (BiCNU)== | ==Cisplatin (Platinol), Dacarbazine (DTIC) +/- Carmustine (BiCNU)== | ||
Line 116: | Line 120: | ||
==CVD, IL-2, IFN alfa-2b - sequential biochemotherapy== | ==CVD, IL-2, IFN alfa-2b - sequential biochemotherapy== | ||
CVD: '''<u>C</u>'''isplatin, '''<u>V</u>'''inblastine, '''<u>D</u>'''acarbazine | CVD: '''<u>C</u>'''isplatin, '''<u>V</u>'''inblastine, '''<u>D</u>'''acarbazine | ||
+ | |||
+ | ===Example orders=== | ||
+ | *[[Example orders for CVD, IL-2, IFN alfa-2b - sequential biochemotherapy in melanoma]] | ||
+ | |||
===Regimen #1, McDermott, et al. 2000 & Atkins, et al. 2008=== | ===Regimen #1, McDermott, et al. 2000 & Atkins, et al. 2008=== | ||
*[[Cisplatin (Platinol)]] 20 mg/m2 IV over 30 minutes on days 1-4, given first | *[[Cisplatin (Platinol)]] 20 mg/m2 IV over 30 minutes on days 1-4, given first | ||
Line 124: | Line 132: | ||
'''21-day cycles x up to 4 cycles''' | '''21-day cycles x up to 4 cycles''' | ||
− | |||
− | |||
Supportive medications: | Supportive medications: | ||
Line 152: | Line 158: | ||
# Eton O, Legha SS, Bedikian AY, Lee JJ, Buzaid AC, Hodges C, Ring SE, Papadopoulos NE, Plager C, East MJ, Zhan F, Benjamin RS. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol. 2002 Apr 15;20(8):2045-52. [http://jco.ascopubs.org/content/20/8/2045.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/11956264 PubMed] | # Eton O, Legha SS, Bedikian AY, Lee JJ, Buzaid AC, Hodges C, Ring SE, Papadopoulos NE, Plager C, East MJ, Zhan F, Benjamin RS. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol. 2002 Apr 15;20(8):2045-52. [http://jco.ascopubs.org/content/20/8/2045.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/11956264 PubMed] | ||
# Atkins MB, Hsu J, Lee S, Cohen GI, Flaherty LE, Sosman JA, Sondak VK, Kirkwood JM; Eastern Cooperative Oncology Group. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2008 Dec 10;26(35):5748-54. Epub 2008 Nov 10. [http://jco.ascopubs.org/content/26/35/5748.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/19001327 PubMed] | # Atkins MB, Hsu J, Lee S, Cohen GI, Flaherty LE, Sosman JA, Sondak VK, Kirkwood JM; Eastern Cooperative Oncology Group. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2008 Dec 10;26(35):5748-54. Epub 2008 Nov 10. [http://jco.ascopubs.org/content/26/35/5748.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/19001327 PubMed] | ||
+ | |||
+ | ==Dabrafenib (Tafinlar)== | ||
+ | ===Regimen, Long, et al. 2012 (BREAK-MB); Flaherty, et al. 2012; Hauschild, et al. 2012=== | ||
+ | *[[Dabrafenib (Tafinlar)]] 150 mg PO BID | ||
+ | |||
+ | '''given until progression of disease''' | ||
+ | |||
+ | ===References=== | ||
+ | # Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH Jr, Kaempgen E, Martín-Algarra S, Karaszewska B, Mauch C, Chiarion-Sileni V, Martin AM, Swann S, Haney P, Mirakhur B, Guckert ME, Goodman V, Chapman PB. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012 Jul 28;380(9839):358-65. doi: 10.1016/S0140-6736(12)60868-X. Epub 2012 Jun 25. [http://www.sciencedirect.com/science/article/pii/S014067361260868X link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/22735384 PubMed] | ||
+ | # Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB, Puzanov I, Hauschild A, Robert C, Algazi A, Mortier L, Tawbi H, Wilhelm T, Zimmer L, Switzky J, Swann S, Martin AM, Guckert M, Goodman V, Streit M, Kirkwood JM, Schadendorf D. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2012 Nov;13(11):1087-95. doi: 10.1016/S1470-2045(12)70431-X. Epub 2012 Oct 8. [http://www.sciencedirect.com/science/article/pii/S147020451270431X link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/23051966 PubMed] | ||
+ | # Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N, Kudchadkar R, Burris HA 3rd, Falchook G, Algazi A, Lewis K, Long GV, Puzanov I, Lebowitz P, Singh A, Little S, Sun P, Allred A, Ouellet D, Kim KB, Patel K, Weber J. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012 Nov;367(18):1694-703. doi: 10.1056/NEJMoa1210093. Epub 2012 Sep 29. [http://www.nejm.org/doi/full/10.1056/NEJMoa1210093 link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/23020132 PubMed] | ||
+ | |||
+ | ==Dabrafenib & Trametinib== | ||
+ | ===Regimen, Flaherty, et al. 2012=== | ||
+ | *[[Dabrafenib (Tafinlar)]] 150 mg PO BID | ||
+ | *[[Trametinib (Mekinist)]] 2 mg PO once per day | ||
+ | |||
+ | ===References=== | ||
+ | # Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N, Kudchadkar R, Burris HA 3rd, Falchook G, Algazi A, Lewis K, Long GV, Puzanov I, Lebowitz P, Singh A, Little S, Sun P, Allred A, Ouellet D, Kim KB, Patel K, Weber J. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012 Nov;367(18):1694-703. doi: 10.1056/NEJMoa1210093. Epub 2012 Sep 29. [http://www.nejm.org/doi/full/10.1056/NEJMoa1210093 link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/23020132 PubMed] | ||
==Dacarbazine (DTIC)== | ==Dacarbazine (DTIC)== | ||
Line 159: | Line 184: | ||
'''21-day cycles x 8 cycles''' | '''21-day cycles x 8 cycles''' | ||
− | ===Regimen #2, Chapman, et al. 2011=== | + | ===Regimen #2, Chapman, et al. 2011; Hauschild, et al. 2012; Flaherty, et al. 2012=== |
*[[Dacarbazine (DTIC)]] 1000 mg/m2 IV on day 1 | *[[Dacarbazine (DTIC)]] 1000 mg/m2 IV on day 1 | ||
Line 173: | Line 198: | ||
# Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011 Jun 30;364(26):2507-16. Epub 2011 Jun 5. [http://www.nejm.org/doi/full/10.1056/NEJMoa1103782 link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/21639808 PubMed] | # Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011 Jun 30;364(26):2507-16. Epub 2011 Jun 5. [http://www.nejm.org/doi/full/10.1056/NEJMoa1103782 link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/21639808 PubMed] | ||
# Robert C, Thomas L, Bondarenko I, O'Day S, M D JW, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH Jr, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011 Jun 30;364(26):2517-26. Epub 2011 Jun 5. [http://www.nejm.org/doi/full/10.1056/NEJMoa1104621 link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/21639810 PubMed] | # Robert C, Thomas L, Bondarenko I, O'Day S, M D JW, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH Jr, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011 Jun 30;364(26):2517-26. Epub 2011 Jun 5. [http://www.nejm.org/doi/full/10.1056/NEJMoa1104621 link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/21639810 PubMed] | ||
+ | # Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH Jr, Kaempgen E, Martín-Algarra S, Karaszewska B, Mauch C, Chiarion-Sileni V, Martin AM, Swann S, Haney P, Mirakhur B, Guckert ME, Goodman V, Chapman PB. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012 Jul 28;380(9839):358-65. doi: 10.1016/S0140-6736(12)60868-X. Epub 2012 Jun 25. [http://www.sciencedirect.com/science/article/pii/S014067361260868X link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/22735384 PubMed] | ||
+ | # Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, Dummer R, Trefzer U, Larkin JM, Utikal J, Dreno B, Nyakas M, Middleton MR, Becker JC, Casey M, Sherman LJ, Wu FS, Ouellet D, Martin AM, Patel K, Schadendorf D; METRIC Study Group. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012 Jul 12;367(2):107-14. doi: 10.1056/NEJMoa1203421. Epub 2012 Jun 4. [http://www.nejm.org/doi/full/10.1056/NEJMoa1203421 link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/22663011 PubMed] | ||
+ | |||
+ | ==Docetaxel (Taxotere)== | ||
+ | |||
+ | ===Regimen, Aamdal, et al. 1994=== | ||
+ | *[[Docetaxel (Taxotere)]] 100 mg/m2 IV over 60 minutes once on day 1 | ||
+ | |||
+ | '''21-day cycles''' | ||
+ | |||
+ | Supportive medications: | ||
+ | *"No prophylactic treatment with steroids or antihistamines was given." | ||
+ | |||
+ | ===References=== | ||
+ | # Aamdal S, Wolff I, Kaplan S, Paridaens R, Kerger J, Schachter J, Wanders J, Franklin HR, Verweij J. Docetaxel (Taxotere) in advanced malignant melanoma: a phase II study of the EORTC Early Clinical Trials Group. Eur J Cancer. 1994;30A(8):1061-4. '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/7654429 PubMed] | ||
==High-dose (HD) IL-2== | ==High-dose (HD) IL-2== | ||
− | ===Regimen=== | + | |
+ | ===Example orders=== | ||
+ | *[[Example orders for High-dose (HD) IL-2 in melanoma]] | ||
+ | |||
+ | ===Regimen, Atkins, et al. 1999=== | ||
*[[Aldesleukin (Proleukin)|IL-2 - Aldesleukin (Proleukin)]] 600,000 or 720,000 units/kg IV every 8 hours x up to 14 doses per week, on days 1-5 | *[[Aldesleukin (Proleukin)|IL-2 - Aldesleukin (Proleukin)]] 600,000 or 720,000 units/kg IV every 8 hours x up to 14 doses per week, on days 1-5 | ||
**After a 6-9 day rest period, another 14 doses per week given over 5 days is given as described above | **After a 6-9 day rest period, another 14 doses per week given over 5 days is given as described above | ||
'''6-12 weeks per cycle x up to 5 cycles''' | '''6-12 weeks per cycle x up to 5 cycles''' | ||
− | |||
− | |||
Supportive medications: | Supportive medications: | ||
Line 215: | Line 257: | ||
==Ipilimumab (Yervoy)== | ==Ipilimumab (Yervoy)== | ||
+ | |||
+ | ===Example orders=== | ||
+ | *[[Example orders for Ipilimumab (Yervoy) in melanoma]] | ||
+ | |||
===Regimen #1, Hodi, et al. 2010=== | ===Regimen #1, Hodi, et al. 2010=== | ||
*[[Ipilimumab (Yervoy)]] 3 mg/kg IV on day 1 | *[[Ipilimumab (Yervoy)]] 3 mg/kg IV on day 1 | ||
'''21-day cycles x 4 cycles''' | '''21-day cycles x 4 cycles''' | ||
− | |||
− | |||
===Regimen #2, Wolchok, et al. 2010=== | ===Regimen #2, Wolchok, et al. 2010=== | ||
Line 263: | Line 307: | ||
===References=== | ===References=== | ||
# Robert C, Thomas L, Bondarenko I, O'Day S, M D JW, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH Jr, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011 Jun 30;364(26):2517-26. Epub 2011 Jun 5. [http://www.nejm.org/doi/full/10.1056/NEJMoa1104621 link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/21639810 PubMed] | # Robert C, Thomas L, Bondarenko I, O'Day S, M D JW, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH Jr, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011 Jun 30;364(26):2517-26. Epub 2011 Jun 5. [http://www.nejm.org/doi/full/10.1056/NEJMoa1104621 link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/21639810 PubMed] | ||
+ | |||
+ | ==Paclitaxel (Taxol)== | ||
+ | |||
+ | ===Regimen #1, Flaherty, et al. 2012=== | ||
+ | ''This was a therapy option for patients in the control arm of Flaherty, et al. 2012.'' | ||
+ | *[[Paclitaxel (Taxol)]] 175 mg/m2 IV once on day 1 | ||
+ | |||
+ | '''21-day cycles''' | ||
+ | |||
+ | ===Regimen #2, O'Day, et al. 2013 (SYMMETRY)=== | ||
+ | ''This was the control arm in O'Day, et al. 2013, which was a negative study.'' | ||
+ | *[[Paclitaxel (Taxol)]] 80 mg/m2 IV once per day on days 1, 8, 15 | ||
+ | |||
+ | '''28-day cycles, given until progression of disease or unacceptable toxicity''' | ||
+ | |||
+ | ===References=== | ||
+ | # Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, Dummer R, Trefzer U, Larkin JM, Utikal J, Dreno B, Nyakas M, Middleton MR, Becker JC, Casey M, Sherman LJ, Wu FS, Ouellet D, Martin AM, Patel K, Schadendorf D; METRIC Study Group. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012 Jul 12;367(2):107-14. doi: 10.1056/NEJMoa1203421. Epub 2012 Jun 4. [http://www.nejm.org/doi/full/10.1056/NEJMoa1203421 link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/22663011 PubMed] | ||
+ | # O'Day SJ, Eggermont AM, Chiarion-Sileni V, Kefford R, Grob JJ, Mortier L, Robert C, Schachter J, Testori A, Mackiewicz J, Friedlander P, Garbe C, Ugurel S, Collichio F, Guo W, Lufkin J, Bahcall S, Vukovic V, Hauschild A. Final results of phase III SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanoma. J Clin Oncol. 2013 Mar 20;31(9):1211-8. doi: 10.1200/JCO.2012.44.5585. Epub 2013 Feb 11. [http://jco.ascopubs.org/content/31/9/1211.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/23401447 PubMed] | ||
==Temozolomide (Temodar)== | ==Temozolomide (Temodar)== | ||
Line 272: | Line 334: | ||
===References=== | ===References=== | ||
# Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, Gore M, Aamdal S, Cebon J, Coates A, Dreno B, Henz M, Schadendorf D, Kapp A, Weiss J, Fraass U, Statkevich P, Muller M, Thatcher N. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000 Jan;18(1):158-66. [http://jco.ascopubs.org/content/18/1/158.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/10623706 PubMed] | # Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, Gore M, Aamdal S, Cebon J, Coates A, Dreno B, Henz M, Schadendorf D, Kapp A, Weiss J, Fraass U, Statkevich P, Muller M, Thatcher N. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000 Jan;18(1):158-66. [http://jco.ascopubs.org/content/18/1/158.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/10623706 PubMed] | ||
+ | |||
+ | ==Trametinib (Mekinist)== | ||
+ | ===Regimen, Flaherty, et al. 2012 (METRIC); Falchook, et al. 2012; Kim, et al. 2013=== | ||
+ | *[[Trametinib (Mekinist)]] 2 mg PO once per day | ||
+ | |||
+ | ===References=== | ||
+ | # Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, Dummer R, Trefzer U, Larkin JM, Utikal J, Dreno B, Nyakas M, Middleton MR, Becker JC, Casey M, Sherman LJ, Wu FS, Ouellet D, Martin AM, Patel K, Schadendorf D; METRIC Study Group. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012 Jul 12;367(2):107-14. doi: 10.1056/NEJMoa1203421. Epub 2012 Jun 4. [http://www.nejm.org/doi/full/10.1056/NEJMoa1203421 link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/22663011 PubMed] | ||
+ | # Falchook GS, Lewis KD, Infante JR, Gordon MS, Vogelzang NJ, DeMarini DJ, Sun P, Moy C, Szabo SA, Roadcap LT, Peddareddigari VG, Lebowitz PF, Le NT, Burris HA 3rd, Messersmith WA, O'Dwyer PJ, Kim KB, Flaherty K, Bendell JC, Gonzalez R, Kurzrock R, Fecher LA. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol. 2012 Aug;13(8):782-9. doi: 10.1016/S1470-2045(12)70269-3. Epub 2012 Jul 16. [http://www.sciencedirect.com/science/article/pii/S1470204512702693 link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/22805292 PubMed] | ||
+ | # Kim KB, Kefford R, Pavlick AC, Infante JR, Ribas A, Sosman JA, Fecher LA, Millward M, McArthur GA, Hwu P, Gonzalez R, Ott PA, Long GV, Gardner OS, Ouellet D, Xu Y, DeMarini DJ, Le NT, Patel K, Lewis KD. Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol. 2013 Feb 1;31(4):482-9. doi: 10.1200/JCO.2012.43.5966. Epub 2012 Dec 17. [http://jco.ascopubs.org/content/31/4/482.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/23248257 PubMed] | ||
==Vemurafenib (Zelboraf)== | ==Vemurafenib (Zelboraf)== |
Revision as of 08:06, 30 May 2013
Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.
Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.
Carboplatin & Paclitaxel (CP)
CP: Carboplatin, Paclitaxel
Regimen #1, Rao, et al. 2006
- Carboplatin (Paraplatin) AUC 2 IV on days 1, 8, 15
- Paclitaxel (Taxol) 100 mg/m2 IV on days 1, 8, 15
28-day cycles
Regimen #2, Rao, et al. 2006
- Carboplatin (Paraplatin) AUC 5 IV on day 1
- Paclitaxel (Taxol) 175-200 mg/m2 IV on day 1
21-day cycles
Regimen #3, Hauschild, et al. 2009 & Flaherty, et al. 2013 (E2603)
- Carboplatin (Paraplatin) AUC 6 IV over 30 minutes once on day 1, given second
- Paclitaxel (Taxol) 225 mg/m2 IV over 3 hours once on day 1, given first
21-day cycles x 4 cycles, then
- Carboplatin (Paraplatin) AUC 5 IV over 30 minutes once on day 1, given second
- Paclitaxel (Taxol) 175 mg/m2 IV over 3 hours once on day 1, given first
21-day cycles x 6 cycles, until progression of disease, or unacceptable toxicity
References
- Rao RD, Holtan SG, Ingle JN, Croghan GA, Kottschade LA, Creagan ET, Kaur JS, Pitot HC, Markovic SN. Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma. Cancer. 2006 Jan 15;106(2):375-82. link to original article contains verified protocol PubMed
- Hauschild A, Agarwala SS, Trefzer U, Hogg D, Robert C, Hersey P, Eggermont A, Grabbe S, Gonzalez R, Gille J, Peschel C, Schadendorf D, Garbe C, O'Day S, Daud A, White JM, Xia C, Patel K, Kirkwood JM, Keilholz U. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol. 2009 Jun 10;27(17):2823-30. Epub 2009 Apr 6. link to original article contains verified protocol PubMed
- Flaherty KT, Lee SJ, Zhao F, Schuchter LM, Flaherty L, Kefford R, Atkins MB, Leming P, Kirkwood JM. Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma. J Clin Oncol. 2013 Jan 20;31(3):373-9. doi: 10.1200/JCO.2012.42.1529. Epub 2012 Dec 17. link to original article contains verified protocol PubMed
Carboplatin, Paclitaxel, Sorafenib
Regimen, Hauschild, et al. 2009 & Flaherty, et al. 2013 (E2603)
Hauschild, et al. 2009 and Flaherty, et al. 2013 (E2603) were negative studies. They did not show improved outcomes for Carboplatin, Paclitaxel, Sorafenib as compared to Carboplatin and Paclitaxel.
- Carboplatin (Paraplatin) AUC 6 IV over 30 minutes once on day 1, given second
- Paclitaxel (Taxol) 225 mg/m2 IV over 3 hours once on day 1, given first
- Sorafenib (Nexavar) 400 mg PO BID on days 2 to 19
21-day cycles x 4 cycles, then
- Carboplatin (Paraplatin) AUC 5 IV over 30 minutes once on day 1, given second
- Paclitaxel (Taxol) 175 mg/m2 IV over 3 hours once on day 1, given first
- Sorafenib (Nexavar) 400 mg PO BID on days 2 to 19
21-day cycles x 6 cycles, until progression of disease, or unacceptable toxicity; then proceed to sorafenib monotherapy
Sorafenib monotherapy
- Sorafenib (Nexavar) 400 mg PO BID on days 1 to 21
21-day cycles, given until progression of disease or unacceptable toxicity
References
- Hauschild A, Agarwala SS, Trefzer U, Hogg D, Robert C, Hersey P, Eggermont A, Grabbe S, Gonzalez R, Gille J, Peschel C, Schadendorf D, Garbe C, O'Day S, Daud A, White JM, Xia C, Patel K, Kirkwood JM, Keilholz U. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol. 2009 Jun 10;27(17):2823-30. Epub 2009 Apr 6. link to original article contains verified protocol PubMed
- Flaherty KT, Lee SJ, Zhao F, Schuchter LM, Flaherty L, Kefford R, Atkins MB, Leming P, Kirkwood JM. Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma. J Clin Oncol. 2013 Jan 20;31(3):373-9. doi: 10.1200/JCO.2012.42.1529. Epub 2012 Dec 17. link to original article contains verified protocol PubMed
Cisplatin (Platinol), Dacarbazine (DTIC) +/- Carmustine (BiCNU)
Regimen
- Cisplatin (Platinol) 75 mg/m2 IV on day 1
- Dacarbazine (DTIC) 800 mg/m2 IV on day 1
- Optional: Carmustine (BiCNU) 100 mg/m2 (note: in Ridolfi, et al. 2002, in contrast to the treatment text, figure 1 lists a dosage of 150 mg/m2) IV on day 1
21-day cycles x 6 cycles
References
- Ridolfi R, Chiarion-Sileni V, Guida M, Romanini A, Labianca R, Freschi A, Lo Re G, Nortilli R, Brugnara S, Vitali P, Nanni O; Italian Melanoma Intergroup. Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial. J Clin Oncol. 2002 Mar 15;20(6):1600-7. link to original article contains verified protocol PubMed
Cisplatin (Platinol), Dacarbazine (DTIC), IL-2, IFN alfa-2b +/- Carmustine (BiCNU)
Regimen
- Cisplatin (Platinol) 75 mg/m2 IV on day 1
- Dacarbazine (DTIC) 800 mg/m2 IV on day 1
- Optional: Carmustine (BiCNU) 100 mg/m2 (note: in Ridolfi, et al. 2002, in contrast to the treatment text, figure 1 lists a dosage of 150 mg/m2) IV on day 1
- IL-2 - Aldesleukin (Proleukin) 4,500,000 units/m2 SC on days 3-5, 8-12
- Interferon alfa-2b (Intron-A) 3,000,000 units/m2 IM on days 3-5 of week 1, then 3 times per week on all later weeks
21-day cycles x 6 cycles
References
- Ridolfi R, Chiarion-Sileni V, Guida M, Romanini A, Labianca R, Freschi A, Lo Re G, Nortilli R, Brugnara S, Vitali P, Nanni O; Italian Melanoma Intergroup. Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial. J Clin Oncol. 2002 Mar 15;20(6):1600-7. link to original article contains verified protocol PubMed
Cisplatin (Platinol), Paclitaxel (Taxol), Dacarbazine (DTIC)
Regimen
- Cisplatin (Platinol) 20 mg/m2 IV on days 1-4
- Paclitaxel (Taxol) 100-120 mg/m2 IV on days 1 & 8
- Dacarbazine (DTIC) 800 mg/m2 IV on day 1
References
- Papadopoulos NE, Bedikian A, Ring S, Kim KB, Hwu WJ, Gerber DL, Homsi J, Hwu P. Phase I/II Study of a Cisplatin-Taxol-Dacarbazine Regimen in Metastatic Melanoma. Am J Clin Oncol. 2009 Oct;32(5):509-14. link to original article contains protocol PubMed
CVD
CVD: Cisplatin, Vinblastine, Dacarbazine
Regimen #1, McDermott, et al. 2000 & Atkins, et al. 2008
- Cisplatin (Platinol) 20 mg/m2 IV over 30 minutes on days 1-4, given first
- Vinblastine (Velban) 1.2 mg/m2 IV push on days 1-4, given second
- Dacarbazine (DTIC) 800 mg/m2 IV over 1 hour on day 1, given third
21-day cycles x up to 4 cycles
Supportive medications:
- Antiemetics and Dexamethasone (Decadron) premedication for chemotherapy
Regimen #2, Eton, et al. 2002
- Cisplatin (Platinol) 20 mg/m2 IV on days 1-4, 22-25
- Vinblastine (Velban) 2 mg/m2 IV on days 1-4, 22-25
- Dacarbazine (DTIC) 800 mg/m2 IV on days 1 & 22
6-week cycles x up to 5 cycles
References
- McDermott DF, Mier JW, Lawrence DP, van den Brink MR, Clancy MA, Rubin KM, Atkins MB. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma. Clin Cancer Res. 2000 Jun;6(6):2201-8. link to original article contains verified protocol PubMed
- Eton O, Legha SS, Bedikian AY, Lee JJ, Buzaid AC, Hodges C, Ring SE, Papadopoulos NE, Plager C, East MJ, Zhan F, Benjamin RS. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol. 2002 Apr 15;20(8):2045-52. link to original article contains verified protocol PubMed content property of HemOnc.org
- Atkins MB, Hsu J, Lee S, Cohen GI, Flaherty LE, Sosman JA, Sondak VK, Kirkwood JM; Eastern Cooperative Oncology Group. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2008 Dec 10;26(35):5748-54. Epub 2008 Nov 10. link to original article contains verified protocol PubMed
CVD, IL-2, IFN alfa-2b - sequential biochemotherapy
CVD: Cisplatin, Vinblastine, Dacarbazine
Example orders
Regimen #1, McDermott, et al. 2000 & Atkins, et al. 2008
- Cisplatin (Platinol) 20 mg/m2 IV over 30 minutes on days 1-4, given first
- Vinblastine (Velban) 1.2 mg/m2 IV push on days 1-4, given second
- Dacarbazine (DTIC) 800 mg/m2 IV over 1 hour on day 1, given third
- IL-2 - Aldesleukin (Proleukin) 9,000,000 units/m2/day IV continuous infusion over 96 hours on days 1-4
- Interferon alfa-2b (Intron-A) 5,000,000 units/m2 SC on days 1-5, 8, 10, 12; days 8, 10, 12 given as outpatient doses
21-day cycles x up to 4 cycles
Supportive medications:
- All antihypertensive therapy discontinued at least 24 hours before each cycle
- Cephalexin (Keflex) or Ciprofloxacin (Cipro) 250 mg PO BID on days 1-14
- Filgrastim (Neupogen) 5 mcg/kg SC on days 7-16, or until ANC >10,000
- Ondansetron (Zofran) 32 mg IV daily
- Lorazepam (Ativan) 1 mg PO/IV every 6 hours
- Acetaminophen (Tylenol) 650 mg PO every 6 hours
- Ranitidine (Zantac) 150 mg PO every 12 hours
- Hydroxyzine (Atarax) 25-50 mg PO or Diphenhydramine (Benadryl) 25 mg PO every 6 hours for pruritis
- Meperidine (Demerol) 25-50 mg IV every 3 hours for chills and rigors
- Antidiarrheals & anxiolytics as needed
Regimen #2, Eton, et al. 2002
- Cisplatin (Platinol) 20 mg/m2 IV on days 1-4, 22-25
- Vinblastine (Velban) 1.5 mg/m2 IV on days 1-4, 22-25
- Dacarbazine (DTIC) 800 mg/m2 IV on days 1 & 22
- IL-2 - Aldesleukin (Proleukin) 9,000,000 units/m2/day IV continuous infusion over 96 hours on days 5-8, 17-20, 26-29
- Interferon alfa-2b (Intron-A) 5,000,000 units/m2 SC on days 5-9, 17-21, 26-30
6-week cycles x up to 5 cycles
References
- McDermott DF, Mier JW, Lawrence DP, van den Brink MR, Clancy MA, Rubin KM, Atkins MB. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma. Clin Cancer Res. 2000 Jun;6(6):2201-8. link to original article contains verified protocol PubMed
- Eton O, Legha SS, Bedikian AY, Lee JJ, Buzaid AC, Hodges C, Ring SE, Papadopoulos NE, Plager C, East MJ, Zhan F, Benjamin RS. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol. 2002 Apr 15;20(8):2045-52. link to original article contains verified protocol PubMed
- Atkins MB, Hsu J, Lee S, Cohen GI, Flaherty LE, Sosman JA, Sondak VK, Kirkwood JM; Eastern Cooperative Oncology Group. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2008 Dec 10;26(35):5748-54. Epub 2008 Nov 10. link to original article contains verified protocol PubMed
Dabrafenib (Tafinlar)
Regimen, Long, et al. 2012 (BREAK-MB); Flaherty, et al. 2012; Hauschild, et al. 2012
- Dabrafenib (Tafinlar) 150 mg PO BID
given until progression of disease
References
- Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH Jr, Kaempgen E, Martín-Algarra S, Karaszewska B, Mauch C, Chiarion-Sileni V, Martin AM, Swann S, Haney P, Mirakhur B, Guckert ME, Goodman V, Chapman PB. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012 Jul 28;380(9839):358-65. doi: 10.1016/S0140-6736(12)60868-X. Epub 2012 Jun 25. link to original article contains verified protocol PubMed
- Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB, Puzanov I, Hauschild A, Robert C, Algazi A, Mortier L, Tawbi H, Wilhelm T, Zimmer L, Switzky J, Swann S, Martin AM, Guckert M, Goodman V, Streit M, Kirkwood JM, Schadendorf D. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2012 Nov;13(11):1087-95. doi: 10.1016/S1470-2045(12)70431-X. Epub 2012 Oct 8. link to original article contains verified protocol PubMed
- Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N, Kudchadkar R, Burris HA 3rd, Falchook G, Algazi A, Lewis K, Long GV, Puzanov I, Lebowitz P, Singh A, Little S, Sun P, Allred A, Ouellet D, Kim KB, Patel K, Weber J. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012 Nov;367(18):1694-703. doi: 10.1056/NEJMoa1210093. Epub 2012 Sep 29. link to original article contains verified protocol PubMed
Dabrafenib & Trametinib
Regimen, Flaherty, et al. 2012
- Dabrafenib (Tafinlar) 150 mg PO BID
- Trametinib (Mekinist) 2 mg PO once per day
References
- Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N, Kudchadkar R, Burris HA 3rd, Falchook G, Algazi A, Lewis K, Long GV, Puzanov I, Lebowitz P, Singh A, Little S, Sun P, Allred A, Ouellet D, Kim KB, Patel K, Weber J. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012 Nov;367(18):1694-703. doi: 10.1056/NEJMoa1210093. Epub 2012 Sep 29. link to original article contains verified protocol PubMed
Dacarbazine (DTIC)
Regimen #1, Robert, et al. 2011
- Dacarbazine (DTIC) 850 mg/m2 IV on day 1
21-day cycles x 8 cycles
Regimen #2, Chapman, et al. 2011; Hauschild, et al. 2012; Flaherty, et al. 2012
- Dacarbazine (DTIC) 1000 mg/m2 IV on day 1
21-day cycles, given until progression of disease or unacceptable toxicity
Regimen #3, Middleton, et al. 2000
- Dacarbazine (DTIC) 250 mg/m2 IV over 30 minutes on days 1-5
21-day cycles, given until progression of disease or unacceptable toxicity
References
- Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, Gore M, Aamdal S, Cebon J, Coates A, Dreno B, Henz M, Schadendorf D, Kapp A, Weiss J, Fraass U, Statkevich P, Muller M, Thatcher N. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000 Jan;18(1):158-66. link to original article contains verified protocol PubMed
- Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011 Jun 30;364(26):2507-16. Epub 2011 Jun 5. link to original article contains verified protocol PubMed
- Robert C, Thomas L, Bondarenko I, O'Day S, M D JW, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH Jr, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011 Jun 30;364(26):2517-26. Epub 2011 Jun 5. link to original article contains verified protocol PubMed
- Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH Jr, Kaempgen E, Martín-Algarra S, Karaszewska B, Mauch C, Chiarion-Sileni V, Martin AM, Swann S, Haney P, Mirakhur B, Guckert ME, Goodman V, Chapman PB. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012 Jul 28;380(9839):358-65. doi: 10.1016/S0140-6736(12)60868-X. Epub 2012 Jun 25. link to original article contains verified protocol PubMed
- Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, Dummer R, Trefzer U, Larkin JM, Utikal J, Dreno B, Nyakas M, Middleton MR, Becker JC, Casey M, Sherman LJ, Wu FS, Ouellet D, Martin AM, Patel K, Schadendorf D; METRIC Study Group. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012 Jul 12;367(2):107-14. doi: 10.1056/NEJMoa1203421. Epub 2012 Jun 4. link to original article contains verified protocol PubMed
Docetaxel (Taxotere)
Regimen, Aamdal, et al. 1994
- Docetaxel (Taxotere) 100 mg/m2 IV over 60 minutes once on day 1
21-day cycles
Supportive medications:
- "No prophylactic treatment with steroids or antihistamines was given."
References
- Aamdal S, Wolff I, Kaplan S, Paridaens R, Kerger J, Schachter J, Wanders J, Franklin HR, Verweij J. Docetaxel (Taxotere) in advanced malignant melanoma: a phase II study of the EORTC Early Clinical Trials Group. Eur J Cancer. 1994;30A(8):1061-4. contains protocol PubMed
High-dose (HD) IL-2
Example orders
Regimen, Atkins, et al. 1999
- IL-2 - Aldesleukin (Proleukin) 600,000 or 720,000 units/kg IV every 8 hours x up to 14 doses per week, on days 1-5
- After a 6-9 day rest period, another 14 doses per week given over 5 days is given as described above
6-12 weeks per cycle x up to 5 cycles
Supportive medications:
- Included Acetaminophen (Tylenol), Indomethacin (Indocin), Meperidine (Demerol), Ranitidine (Zantac), Cimetidine (Tagamet), Hydroxyzine (Atarax), Diphenhydramine (Benadryl), dopamine, phenylephrine, antidiarrheals, antiemetics, anxiolytics, diuretics, and, if needed, antibiotics.
References
- Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D, Hawkins M, Paradise C, Kunkel L, Rosenberg SA. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999 Jul;17(7):2105-16. link to original article contains verified protocol PubMed
- Atkins MB, Kunkel L, Sznol M, Rosenberg SA. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am. 2000 Feb;6 Suppl 1:S11-4. PubMed
IL-2 maintenance biotherapy
Regimen
Low-dose cycles 1, 4, 7, 9, 11:
- IL-2 - Aldesleukin (Proleukin) 1,000,000 units/m2 SC every Monday-Friday on days 1-28
- Sargramostim (Leukine) 125 mcg/m2 SC on days 1-14
28-day cycles x a total of 12 cycles after being combined with the pulse cycles below
Pulse cycles 2, 3, 5, 6, 8, 10, 12:
- IL-2 - Aldesleukin (Proleukin) 18,000,000 units/m2 IV continuous infusion over 6 hours, then 18,000,000 units/m2 IV continuous infusion over 12 hours, then 18,000,000 units/m2 IV continuous infusion over 24 hours on days 1-2
- Then as an outpatient: IL-2 - Aldesleukin (Proleukin) 1,000,000 units/m2 SC every Monday-Friday on days 3-28
- Sargramostim (Leukine) 125 mcg/m2 SC on days 3-17 (note: this was possibly a typo in the regimen since shifting the schedule 2 days forward would be days 3-16)
28-day cycles x a total of 12 cycles after being combined with the low dose cycles above
Supportive medications:
- Ondansetron (Zofran) 32 mg IV or Granisetron (Kytril) 2 mg IV daily
- Omeprazole (Prilosec) 20 mg PO QPM
- Acetaminophen (Tylenol) 650 mg PO every 4 hours, starting prior to IL-2 and continuing on days 1-2
- Meperidine (Demerol) 25 mg IV every 6 hours as needed for chills and rigors
References
- O'Day SJ, Boasberg PD, Piro L, Kristedja TS, Wang HJ, Martin M, Deck R, Ames P, Shinn K, Kim H, Fournier P, Gammon G. Maintenance biotherapy for metastatic melanoma with interleukin-2 and granulocyte macrophage-colony stimulating factor improves survival for patients responding to induction concurrent biochemotherapy. Clin Cancer Res. 2002 Sep;8(9):2775-81. link to original article contains verified protocol PubMed
Ipilimumab (Yervoy)
Example orders
Regimen #1, Hodi, et al. 2010
- Ipilimumab (Yervoy) 3 mg/kg IV on day 1
21-day cycles x 4 cycles
Regimen #2, Wolchok, et al. 2010
- Ipilimumab (Yervoy) 10 mg/kg IV over 90 minutes on day 1
- Lower doses including 3 mg/kg (the FDA approved dose) were investigated, but the 10 mg/kg dose was recommended in this study
21-day cycles x 4 cycles
Regimen #3, O'Day, et al. 2010
Induction phase:
- Ipilimumab (Yervoy) 10 mg/kg IV over 90 minutes on day 1
21-day cycles x 4 cycles
Maintenance phase:
- Ipilimumab (Yervoy) 10 mg/kg IV over 90 minutes on day 1
12-week cycles, given until progression of disease or unacceptable toxicity; starts 12 weeks after completion of induction phase
References
- Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, Waterfield W, Schadendorf D, Smylie M, Guthrie T Jr, Grob JJ, Chesney J, Chin K, Chen K, Hoos A, O'Day SJ, Lebbé C. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010 Feb;11(2):155-64. Epub 2009 Dec 8. link to original article contains verified protocol PubMed
- Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010 Aug 19;363(8):711-23. Epub 2010 Jun 5. link to original article contains verified protocol PubMed
- O'Day SJ, Maio M, Chiarion-Sileni V, Gajewski TF, Pehamberger H, Bondarenko IN, Queirolo P, Lundgren L, Mikhailov S, Roman L, Verschraegen C, Humphrey R, Ibrahim R, de Pril V, Hoos A, Wolchok JD. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol. 2010 Aug;21(8):1712-7. Epub 2010 Feb 10. link to original article contains verified protocol PubMed
Ipilimumab (Yervoy) & Dacarbazine (DTIC)
Regimen
Induction phase:
- Ipilimumab (Yervoy) 10 mg/kg IV on day 1
- Dacarbazine (DTIC) 850 mg/m2 IV on day 1
21-day cycles x 4 cycles, then
- Dacarbazine (DTIC) 850 mg/m2 IV on day 1
21-day cycles x 4 cycles; if patient has stable disease or objective response, proceed to maintenance phase
Maintenance phase:
- Ipilimumab (Yervoy) 10 mg/kg IV on day 1
12-week cycles, given until progression of disease or unacceptable toxicity
References
- Robert C, Thomas L, Bondarenko I, O'Day S, M D JW, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH Jr, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011 Jun 30;364(26):2517-26. Epub 2011 Jun 5. link to original article contains verified protocol PubMed
Paclitaxel (Taxol)
Regimen #1, Flaherty, et al. 2012
This was a therapy option for patients in the control arm of Flaherty, et al. 2012.
- Paclitaxel (Taxol) 175 mg/m2 IV once on day 1
21-day cycles
Regimen #2, O'Day, et al. 2013 (SYMMETRY)
This was the control arm in O'Day, et al. 2013, which was a negative study.
- Paclitaxel (Taxol) 80 mg/m2 IV once per day on days 1, 8, 15
28-day cycles, given until progression of disease or unacceptable toxicity
References
- Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, Dummer R, Trefzer U, Larkin JM, Utikal J, Dreno B, Nyakas M, Middleton MR, Becker JC, Casey M, Sherman LJ, Wu FS, Ouellet D, Martin AM, Patel K, Schadendorf D; METRIC Study Group. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012 Jul 12;367(2):107-14. doi: 10.1056/NEJMoa1203421. Epub 2012 Jun 4. link to original article contains verified protocol PubMed
- O'Day SJ, Eggermont AM, Chiarion-Sileni V, Kefford R, Grob JJ, Mortier L, Robert C, Schachter J, Testori A, Mackiewicz J, Friedlander P, Garbe C, Ugurel S, Collichio F, Guo W, Lufkin J, Bahcall S, Vukovic V, Hauschild A. Final results of phase III SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanoma. J Clin Oncol. 2013 Mar 20;31(9):1211-8. doi: 10.1200/JCO.2012.44.5585. Epub 2013 Feb 11. link to original article contains verified protocol PubMed
Temozolomide (Temodar)
Regimen
- Temozolomide (Temodar) 200 mg/m2 PO on days 1-5, taken while fasting
28-day cycles, given until progression of disease or unacceptable toxicity
References
- Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, Gore M, Aamdal S, Cebon J, Coates A, Dreno B, Henz M, Schadendorf D, Kapp A, Weiss J, Fraass U, Statkevich P, Muller M, Thatcher N. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000 Jan;18(1):158-66. link to original article contains verified protocol PubMed
Trametinib (Mekinist)
Regimen, Flaherty, et al. 2012 (METRIC); Falchook, et al. 2012; Kim, et al. 2013
- Trametinib (Mekinist) 2 mg PO once per day
References
- Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, Dummer R, Trefzer U, Larkin JM, Utikal J, Dreno B, Nyakas M, Middleton MR, Becker JC, Casey M, Sherman LJ, Wu FS, Ouellet D, Martin AM, Patel K, Schadendorf D; METRIC Study Group. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012 Jul 12;367(2):107-14. doi: 10.1056/NEJMoa1203421. Epub 2012 Jun 4. link to original article contains verified protocol PubMed
- Falchook GS, Lewis KD, Infante JR, Gordon MS, Vogelzang NJ, DeMarini DJ, Sun P, Moy C, Szabo SA, Roadcap LT, Peddareddigari VG, Lebowitz PF, Le NT, Burris HA 3rd, Messersmith WA, O'Dwyer PJ, Kim KB, Flaherty K, Bendell JC, Gonzalez R, Kurzrock R, Fecher LA. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol. 2012 Aug;13(8):782-9. doi: 10.1016/S1470-2045(12)70269-3. Epub 2012 Jul 16. link to original article contains verified protocol PubMed
- Kim KB, Kefford R, Pavlick AC, Infante JR, Ribas A, Sosman JA, Fecher LA, Millward M, McArthur GA, Hwu P, Gonzalez R, Ott PA, Long GV, Gardner OS, Ouellet D, Xu Y, DeMarini DJ, Le NT, Patel K, Lewis KD. Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol. 2013 Feb 1;31(4):482-9. doi: 10.1200/JCO.2012.43.5966. Epub 2012 Dec 17. link to original article contains verified protocol PubMed
Vemurafenib (Zelboraf)
Regimen
- Vemurafenib (Zelboraf) 960 mg PO BID
given until progression of disease or unacceptable toxicity
References
- Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011 Jun 30;364(26):2507-16. Epub 2011 Jun 5. link to original article contains verified protocol PubMed